Museado / NARA Collection wjc-dpc — Collection wjc-dpc
Recent Folios
Login Register
English español (Spanish) magyar (Hungarian) हिन्दी (Hindi)

Survos folio row show

Children's Health-Pediatric Labeling [2]

Citation Source image
Login to bookmark
Edit Ask document Ask page OCR Handwriting
Page 1 of 73

Images (73)

Open viewer
p. 1
p. 2
p. 3
p. 4
p. 5
p. 6
p. 7
p. 8
p. 9
p. 10
p. 11
p. 12
p. 13
p. 14
p. 15
p. 16
p. 17
p. 18
p. 19
p. 20
p. 21
p. 22
p. 23
p. 24
p. 25
p. 26
p. 27
p. 28
p. 29
p. 30
p. 31
p. 32
p. 33
p. 34
p. 35
p. 36
p. 37
p. 38
p. 39
p. 40
p. 41
p. 42
p. 43
p. 44
p. 45
p. 46
p. 47
p. 48
p. 49
p. 50
p. 51
p. 52
p. 53
p. 54
p. 55
p. 56
p. 57
p. 58
p. 59
p. 60
Showing first 60 of 73 pages.

Document

id
id
621035227
contentType
contentType
document
source
source
import
Source image fields (6)
thumbnailUrl https://s3.amazonaws.com/NARAprodstorage/lz/presidential-libraries/clinton/7763297/7763297-20110688S-010-007-2025/7763297-20110688S-010-007-2025-001.jpg
largeImageUrl https://s3.amazonaws.com/NARAprodstorage/lz/presidential-libraries/clinton/7763297/7763297-20110688S-010-007-2025/7763297-20110688S-010-007-2025-001.jpg
iiifBase https://s3.amazonaws.com/NARAprodstorage/lz/presidential-libraries/clinton/7763297/7763297-20110688S-010-007-2025/7763297-20110688S-010-007-2025-001.jpg
imageCount 73
hasImages 1
sourceUrl https://catalog.archives.gov/id/621035227

Extracted text

OCR Page 1 of 73
AUG - 7 1997 COPY DEPARTMENT OF HEALTH AND HUMAN SERVICES NIF - 7 Food and Drug Administration 21 CFR Parts 200, 312, 314, and 601 [Docket No. 97N-0165] RIN 0910-AB20 Regulations Requiring Manufacturers to Assess the Safety and Effectiveness of New Drugs and Biological Products in Pediatric Patients AGENCY: Food and Drug Administration, HHS. ACTION: Proposed rule. SUMMARY: The Food and Drug Administration (FDA) is proposing new regulations requiring pediatric studies of certain new drug and biological products. Many new drugs and biological products represent treatments that are, at least at times, the best available treatment for children, but most of them have not been adequately tested in the pediatric subpopulation. As a result, product labeling frequently fails to provide directions for safe and effective use in pediatric patients. The proposed rule would attempt to partially address this lack of pediatric use information by requiring that manufacturers of a limited class of new drugs and new biological products provide sufficient data and information to support directions for pediatric use for the claimed indications, before or soon after approval. Manufacturers of a limited class of marketed drugs and biologics would also in compelling circumstances have to provide such data. This proposed rule is part of a comprehensive effort to increase the number of new drugs and biological products with clinically oc97113 1,

Relations

belongs_to
belongs_to